STAT Plus: Unbowed by critics, Gilead’s cancer chief pushes ahead with growth plans
HYACINTH EMPINADO/STAT
Gilead Sciences spent years and billions of dollars to build its oncology business, most notably by acquiring Kite Pharma. But that has yet to deliver commercially.
No hay comentarios:
Publicar un comentario